Back to Search
Start Over
Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer
- Source :
- Oncotarget
- Publication Year :
- 2017
-
Abstract
- Successful therapeutic options remain elusive for pancreatic cancer. The exquisite sensitivity and specificity of humoral and cellular immunity may provide therapeutic approaches if antigens specific for pancreatic cancer cells can be identified. Here we characterize SAS1B (ovastacin, ASTL, astacin-like), a cancer-oocyte antigen, as an attractive immunotoxin target expressed at the surface of human pancreatic cancer cells, with limited expression among normal tissues. Immunohistochemistry shows that most pancreatic cancers are SAS1Bpos (68%), while normal pancreatic ductal epithelium is SAS1Bneg. Pancreatic cancer cell lines developed from patient-derived xenograft models display SAS1B cell surface localization, in addition to cytoplasmic expression, suggesting utility for SAS1B in multiple immunotherapeutic approaches. When pancreatic cancer cells were treated with an anti-SAS1B antibody-drug conjugate, significant cell death was observed at 0.01-0.1 μg/mL, while SAS1Bneg human keratinocytes were resistant. Cytotoxicity was correlated with SAS1B cell surface expression; substantial killing was observed for tumors with low steady state SAS1B expression, suggesting a substantial proportion of SAS1Bpos tumors can be targeted in this manner. These results demonstrate SAS1B is a surface target in pancreatic cancer cells capable of binding monoclonal antibodies, internalization, and delivering cytotoxic drug payloads, supporting further development of SAS1B as a novel target for pancreatic cancer.
- Subjects :
- 0301 basic medicine
Cellular immunity
Antibody-drug conjugate
Antibody-Drug Conjugate Therapy
medicine.drug_class
Cell
Monoclonal antibody
antibody-drug conjugate
03 medical and health sciences
0302 clinical medicine
Antigen
Immunotoxin
Pancreatic cancer
Medicine
business.industry
ASTL/SAS1B/ovastacin
surface cancer-oocyte antigen
medicine.disease
3. Good health
030104 developmental biology
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
pancreatic cancer biomarker
Cancer research
targeted immunotherapy
business
Research Paper
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 9
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....ccb2927e5ef649b1457b48de87ba57a2